Table 1.
Clinicopathologic characteristics of patients according to subtypes
| HR+ (N = 71) | HER2+ (N = 14) | TN (N = 25) | P value | |
|---|---|---|---|---|
|
Clinical characteristics at initial diagnosis | ||||
| Median age |
43.8 (30-69) |
49.5 (33-65) |
47.0 (24-77) |
.398A |
| Initial stage | ||||
| I |
9 (12.7%) |
1 (7.1%) |
2 (8.0%) |
|
| II |
23 (32.4%) |
4 (28.6%) |
11 (44.0%) |
|
| III |
11 (15.5%) |
2 (14.3%) |
2 (8.0%) |
|
| IV |
25 (35.2%) |
6 (42.9%) |
9 (36.0%) |
.951B |
| unknown |
3 (4.2%) |
1 (7.1%) |
1 (4.0%) |
|
| Familial History |
16 (23.5%) |
4 (28.6%) |
7 (29.2%) |
.829B |
| DFI after surgery (median) |
47.6 months |
40.6 months |
38.7 months |
0.231 by log-rank test |
|
Tumor characteristics | ||||
| B-R.Gr. III (n = 69) |
17 (37.8%) |
2 (25.0%) |
14 (87.5%) |
*.001B |
| P53 <5% (n = 93) |
32 (55.2%) |
7 (50.0%) |
9 (42.9%) |
.621B |
| Ki 67 >50% (n = 25) |
5 (31.3%) |
0 (0%) |
6 (85.7%) |
*.013B |
|
Previous (neoadjuvant or adjuvant) treatments | ||||
| Curative surgery. |
45 (63.4%) |
8 (57.1%) |
15 (60.0%) |
.888B |
| Neoadju-CTx |
3 (4.2%) |
0 (0%) |
1 (4.0%) |
.573B |
| Adjuvant CTx |
35 (49.3%) |
7 (50.0%) |
12 (48.0%) |
.991B |
| Adjuvant doxorubicin |
6 (17.1%) |
1 (14.3%) |
0 (0%) |
.048B |
| Adjuvant HormoTx |
43 (60.6%) |
0 |
0 |
< 0.0001 B |
|
Distant Metastases | ||||
| Lung |
49 (74.2%) |
11 (84.6%) |
15 (62.5%) |
0.316 |
| Pleura |
41 (57.8%) |
8 (57.4%) |
10 (45.5%) |
0.216 |
| Liver |
33 (52.4%) |
11 (84.6%) |
10 (45.5%) |
0.046 |
| Brain |
11 (17.7%) |
3 (23.1%) |
6 (27.3%) |
0.629 |
| Bone |
36 (50.7%) |
8 (57.1%) |
10 (40.0%) |
0.283 |
| Skin |
14 (19.7%) |
1 (7.1%) |
9 (36%) |
0.081 |
| Soft tissue |
22 (31.0%) |
1 (7.1%) |
6 (24.0%) |
0.120 |
|
Next treatment after AC chemotherapy | ||||
| Median number of CTx (range) |
3 (0-11) |
2 (0-8) |
1 (0-7) |
0.006 |
| Number of patients with HormoTx (%) |
17 (24%) |
0 |
0 |
0.001 |
| Number of patients with trastuzumab Tx (%) | 5 (7.0%) | 4 (28.6%) | 0 | 0.009 |
DFI, disease free interval; CTx, chemotherapy; HormoTx, hormonal therapy; Tx, treatment
AContinuous variables; One way ANOVA
BCategorical variables; Pearson's chi-square test